Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Tomassini

Showing results (41-50 of 117) with videos related to

Pageof 12
Sort By:
Data in Brief|February 24, 2016
Time-related trends in variability of cIMT changes in statin trialsMichael H Davidson, Joanne E Tomassini, Erin Jensen, et al.
Vaccine|January 1, 2008
Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccinesCosette M Wheeler, Oliver M Bautista, Joanne E Tomassini, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 1, 1989
cDNA cloning reveals that the major group rhinovirus receptor on HeLa cells is intercellular adhesion molecule 1J E Tomassini, D Graham, C M DeWitt, et al.
Journal of Clinical Lipidology|February 20, 2016
Inverse relationship between high-density lipoprotein cholesterol raising and high-sensitivity C-reactive protein reduction in older patients treated with lipid-lowering therapyW Virgil Brown, JoAnne M Foody, Franklin J Zieve, et al.
Diabetes Care|February 17, 2012
Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trialJohn R Guyton, Sergio Fazio, Adeniyi J Adewale, et al.
Journal of the American Heart Association|August 9, 2013
Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patientsNgoc-Anh Le, Ran Jin, Joanne E Tomassini, et al.
Lipids in Health and Disease|May 20, 2015
Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based surveyMichel Krempf, Ross J Simpson, Dena Rosen Ramey, et al.
Vaccine|April 21, 2007
Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccineChristophe Fraser, Joanne E Tomassini, Liwen Xi, et al.
Atherosclerosis|October 10, 2014
Combination therapy in dyslipidemia: where are we now?Alberico L Catapano, Michel Farnier, JoAnne M Foody, et al.
Atherosclerosis|October 9, 2012
Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patientsNuntakorn Thongtang, Jianxin Lin, Ernst J Schaefer, et al.
Pageof 12

Showing results (41-50 of 117) with videos related to

Sort By:
Pageof 12
Data in Brief|February 24, 2016
Time-related trends in variability of cIMT changes in statin trialsMichael H Davidson, Joanne E Tomassini, Erin Jensen, et al.
Vaccine|January 1, 2008
Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccinesCosette M Wheeler, Oliver M Bautista, Joanne E Tomassini, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 1, 1989
cDNA cloning reveals that the major group rhinovirus receptor on HeLa cells is intercellular adhesion molecule 1J E Tomassini, D Graham, C M DeWitt, et al.
Journal of Clinical Lipidology|February 20, 2016
Inverse relationship between high-density lipoprotein cholesterol raising and high-sensitivity C-reactive protein reduction in older patients treated with lipid-lowering therapyW Virgil Brown, JoAnne M Foody, Franklin J Zieve, et al.
Diabetes Care|February 17, 2012
Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trialJohn R Guyton, Sergio Fazio, Adeniyi J Adewale, et al.
Journal of the American Heart Association|August 9, 2013
Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patientsNgoc-Anh Le, Ran Jin, Joanne E Tomassini, et al.
Lipids in Health and Disease|May 20, 2015
Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based surveyMichel Krempf, Ross J Simpson, Dena Rosen Ramey, et al.
Vaccine|April 21, 2007
Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccineChristophe Fraser, Joanne E Tomassini, Liwen Xi, et al.
Atherosclerosis|October 10, 2014
Combination therapy in dyslipidemia: where are we now?Alberico L Catapano, Michel Farnier, JoAnne M Foody, et al.
Atherosclerosis|October 9, 2012
Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patientsNuntakorn Thongtang, Jianxin Lin, Ernst J Schaefer, et al.
Pageof 12